Literature DB >> 17408469

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.

Gareth J Morgan, Stephen A Schey, Ping Wu, Muralikrishan Srikanth, Karen J Phekoo, Matthew Jenner, Faith E Davies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17408469     DOI： 10.1111/j.1365-2141.2007.06538.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  16 in total

Review 1.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

2.  Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Authors:  Atsushi Isoda; Naru Sato; Yuri Miyazawa; Yoshinobu Matsumoto; Mina Koumoto; Masahito Ookawa; Morio Sawamura; Morio Matsumoto
Journal:  Int J Hematol       Date:  2015-07-16       Impact factor: 2.490

Review 3.  Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Authors:  J Laubach; L Garderet; A Mahindra; G Gahrton; J Caers; O Sezer; P Voorhees; X Leleu; H E Johnsen; M Streetly; A Jurczyszyn; H Ludwig; U-H Mellqvist; W-J Chng; L Pilarski; H Einsele; J Hou; I Turesson; E Zamagni; C S Chim; A Mazumder; J Westin; J Lu; T Reiman; S Kristinsson; D Joshua; M Roussel; P O'Gorman; E Terpos; P McCarthy; M Dimopoulos; P Moreau; R Z Orlowski; J S Miguel; K C Anderson; A Palumbo; S Kumar; V Rajkumar; B Durie; P G Richardson
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

Review 4.  Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Angelo Vacca
Journal:  World J Methodol       Date:  2014-06-26

Review 5.  Mechanism of action of immunomodulatory agents in multiple myeloma.

Authors:  Thomas Reske; Mariateresa Fulciniti; Nikhil C Munshi
Journal:  Med Oncol       Date:  2010-04-20       Impact factor: 3.064

6.  Thrombosis is associated with inferior survival in multiple myeloma.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Sam Schulman; Ola Landgren
Journal:  Haematologica       Date:  2012-04-17       Impact factor: 9.941

7.  Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authors:  Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth Anderson
Journal:  Core Evid       Date:  2010-06-15

Review 8.  The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

Authors:  J P Laubach; A Mahindra; C S Mitsiades; R L Schlossman; N C Munshi; I M Ghobrial; N Carreau; T Hideshima; K C Anderson; P G Richardson
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

Review 9.  Emerging therapies for multiple myeloma.

Authors:  Klaus Podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

Review 10.  New therapies in multiple myeloma.

Authors:  F Merchionne; F Perosa; F Dammacco
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.